The beneficial effect of vanillic acid on ulcerative colitis

Molecules

Volumn 15, Issue 10, 2010, Pages 7208-7217

  Kim, Su Jin ^a   Kim, Min Cheol ^b   Um, Jae Young ^a   Hong, Seung Heon ^b  

^a Kyung Hee University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Cyclooxygenase 2; Dextran sulfate sodium; Interleukin 6; Nuclear factor B p65; Ulcerative colitis; Vanillic acid

Indexed keywords

CYCLOOXYGENASE 2; DEXTRAN SULFATE; INTERLEUKIN 6; TRANSCRIPTION FACTOR RELA; VANILLIC ACID;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CHEMICALLY INDUCED DISORDER; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; TRANSCRIPTION FACTOR RELA; VANILLIC ACID;

EID: 78149427740     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15107208     Document Type: Article

References (26)

1. Fiocchi, C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115, 182-205.
2. Hyams, J.S. Inflammatory bowel disease. Pediatr. Rev. 2000, 21, 291-295.
3. Danese, S.; Sans, M.; Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun. Rev. 2004, 3, 394-400.
4. Hendrickson, B.A.; Gokhale, R.; Cho, J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15, 79-94.
5. Blumberg, R.S.; Saubermann, L.J.; Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. 1999, 11, 648-656.
6. Ullman, T.; Croog, V.; Harpaz, N.; Sachar, D.; Itzkowitz, S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003, 125, 1311-1319.
7. Li, Y.; de Haar, C.; Chen, M.; Deuring, J.; Gerrits, M.M.; Smits, R.; Xia, B.; Kuipers, E.J.; van der Woude, C.J. Disease-Related Expression of the IL-6 / STAT3 / SOCS3 Signaling Pathway in Ulcerative Colitis and Ulcerative Colitis-Related Carcinogenesis. Gut 2010, 59, 227-235.
8. Agoff, S.N.; Brentnall, T.A.; Crispin, D.A.; Taylor, S.L.; Raaka, S.; Haggitt, R.C.; Reed, M.W.; Afonina, I.A.; Ravinovitch, P.S.; Stevens, A.C.; Feng, Z.; Bronner, M.P. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Amer. J. Pathol. 2000, 157, 737-745.
9. Roberts, P.J.; Morgan, K.; Miller, R.; Hunter, J.O.; Middleton, S.J. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 2001, 48, 468-472.
10. Barnes, P.J.; Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336, 1066-1071.
11. Schaecher, K.; Goust, J.M.; Banik, N.L. The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem. Res. 2004, 29, 1443-1451.
12. Neurath, M.F.; Pettersson, S.; Meyer zum Büschenfelde, K.H.; Strober, W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. 1996, 2, 998-1004.
13. Domènech, E. Inflammatory bowel disease: current therapeutic options. Digestion 2006, 73, 67-76.
14. Lesage-Meessen, L.; Delattre, M.; Haon, M.; Thibault, J.F.; Ceccaldi, B.C.; Brunerie, P.; Asther, M. A two-step bioconversion process for vanillin production from ferulic acid combining Aspergillus niger and Pycnoporus cinnabarinus. J. Biotechnol. 1996, 50, 107-113.
15. Civolani, C.; Barghini, P.; Roncetti, A.R.; Ruzzi, M.; Schiesser, A. Bioconversion of ferulic acid into vanillic acid by means of a vanillate-negative mutant of Pseudomonas fluorescens strain BF13. Appl. Environ. Microbiol. 2000, 66, 2311-2317.
16. Duke, J.A. Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants, 999th ed.; CRC Press: Boca Raton, FL, USA, 1992.
17. Chiang, L.C.; Ng, L.T.; Chiang, W.; Chang, M.Y.; Lin, C.C. Immunomodulatory activities of flavonoids, monoterpenoids, triterpenoids, iridoid glycosides and phenolic compounds of Plantago species. Planta Med. 2003, 69, 600-604.
18. Itoh, A.; Isoda, K.; Kondoh, M.; Kawase, M.; Kobayashi, M.; Tamesada, M.; Yagi, K. Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol. Pharm. Bull. 2009, 32, 1215-1219.
19. Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y.; Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694-702.
20. Fan, H.; Qiu, M.Y.; Mei, J.J.; Shen, G.X.; Liu, S.L.; Chen, R. Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J. Gastroenterol. 2005, 11, 4800-4806.
21. Ardizzone, S.; Bianchi, P.G. Biologic therapy for inflammatory bowel disease. Drugs 2005, 65, 2253-2286.
22. Rufo, P.A.; Bousvaros, A. Current therapy of inflammatory bowel disease in children. Paediatr. Drugs 2006, 8, 279-302.
23. Sato, K.; Ohkura, S.; Kitahara, Y.; Ohama, T.; Hori, M.; Sato, M.; Kobayashi, S.; Sasaki, Y.; Hayashi, T.; Nasu, T.; Ozaki, H. Involvement of CPI-17 downregula in the dysmotility of the colon from dextran sodium sulphate-induced experimental colitis in a mouse model. Neurogastroenterol. Motil. 2007, 19, 504-514.
24. Neurath, M.F.; Fuss, I.; Schürmann, G.; Pettersson, S.; Arnold, K.; Müller-Lobeck, H.; Strober, W.; Herfarth, C.; Büschenfelde, K.H. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1998, 859, 149-159.
25. Murthy, S.N.; Cooper, H.S.; Shim, H.; Shah, R.S.; Ibrahim, S.A.; Sedergran, D.J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dis. Sci. 1993, 38, 1722-1734.
26. Jeong, H.J.; Na, H.J.; Hong, S.H.; Kim, H.M. Inhibition of the stem cell factor-induced migration of mast cells by dexamethasone. Endocrinology 2003, 144, 4080-4086.